Aesica, a global contract manufacturing organisation (CMO), has announced a partnership with the UK’s University of Nottingham to explore the development of alternative methods in amide bond synthesis.
Amide bond formation is fundamental part of pharmaceutical manufacturing, and is utilised in 84% of a set of drug candidates.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The partnership’s aim is to revolutionise traditional amide formation techniques by generating alternative, eco-friendly and chemically versatile methods for amide bond formation.
According to the company, the approach will be commercially available in the next two to three months and the company is already actively seeking commercial opportunities to work with potential compounds that could benefit from this novel technology.
Aesica envisages this new development will lower production costs whilst offering the potential of higher chemical yields.
University of Nottingham Synthetic Organic Chemistry professor Simon Woodward said that one of the departments goals has been to see this novel technology used in larger scale industrial environments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"We look forward to collaborating with Aesica and seeing the full commercial potential of this novel technology in API manufacture," said Woodward.
Aesica Pharmaceuticals Technology Development director Barrie Rhodes said that the new amide production technology will enable cheaper and simpler routes to market for many compounds.
"Professor Woodward’s ability to carry out high calibre research coupled with our desire to bring new economically important and innovative technologies to the market is the basis for a truly collaborative partnership," Rhodes said.
